top of page
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays
At DrugVision.ai , we're committed to pushing the boundaries of organoid drug screening by integrating cutting-edge technologies into our...
Christophe Deben
Dec 5, 20241 min read
46
0
Auranofin Repurposing for Lung and Pancreatic Cancer: Low CA12 Expression as a Marker of Sensitivity in Patient-Derived Organoids, with Potentiated Efficacy by AKT Inhibition.
This study embarked on an ambitious journey, utilizing twenty 384-well microplates, exploring 11 drug synergy combinations, and analyzing...
Christophe Deben
Jan 23, 20241 min read
38
0
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer
In this translational study, we explore pancreatic ductal adenocarcinoma (PDAC) and its inherent treatment resistance, emphasizing the...
Christophe Deben
Jan 23, 20242 min read
13
0
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
In this publication, we introduce an innovative drug screening methodology using patient-derived tumor organoids. This paper focuses on...
Christophe Deben
Jan 23, 20242 min read
33
0
OrBITS: label-free and time-lapse monitoring of patient derivedorganoids for advanced drug screening
In our original manuscript, we delve into the foundational work behind the development of the OrBITS label-free organoid detection...
Christophe Deben
Jan 23, 20242 min read
35
0
bottom of page